Sana CFO Hardy to depart
Plus: New CEOs at Alchemab and Genespire, and more from Leyden and Pharmazz
Sana Biotechnology Inc. (NASDAQ:SANA) disclosed in an SEC filing that EVP and CFO Nathan Hardy will depart on Oct. 4, for personal reasons. A successor to Hardy, who joined the company in 2018, was not disclosed. Sana veteran Doug Williams, whose departure from the cell therapy company was announced in April, became CEO of TriArm Therapeutics (Shanghai) Co. Ltd. this month.
Two companies named new CEOs — Alchemab Therapeutics Ltd., which will be led by Jane Osbourn, and Genespire s.r.l., which hired Karen Aiach-Pignet. Osbourn, who succeeds Young Kwon and joins the board, is a venture partner at Alchemab founding investor SV Health Investors and was Alchemab’s CSO. Aiach-Pignet founded and was chairman and CEO of Lysogene S.A. She succeeds Julia Berretta...